An Antitumor Bis(N-Heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target.

Angew Chem Int Ed Engl

State Key Laboratory of Synthetic Chemistry, Aglaia-KEIIT Laboratory for Drug Discovery and Development and Department of Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong, China.

Published: August 2019

New anticancer platinum(II) compounds with distinctive modes of action are appealing alternatives to combat the drug resistance and improve the efficacy of clinically used platinum chemotherapy. Herein, we describe a rare example of an antitumor Pt complex targeting a tumor-associated protein, rather than DNA, under cellular conditions. Complex [(bis-NHC)Pt(bt)]PF (1 a; Hbt=1-(3-hydroxybenzo[b]thiophen-2-yl)ethanone) overcomes cisplatin resistance in cancer cells and displays significant tumor growth inhibition in mice with higher tolerable doses compared to cisplatin. The cellular Pt species shows little association with DNA, and localizes in the cytoplasm as revealed by nanoscale secondary ion mass spectrometry. An unbiased thermal proteome profiling experiment identified asparagine synthetase (ASNS) as a molecular target of 1 a. Accordingly, 1 a treatment reduced the cellular asparagine levels and inhibited cancer cell proliferation, which could be reversed by asparagine supplementation. A bis-NHC-ligated Pt species generated from the hydrolysis of 1 a forms adducts with thiols and appears to target an active-site cysteine of ASNS.

Download full-text PDF

Source
http://dx.doi.org/10.1002/anie.201904131DOI Listing

Publication Analysis

Top Keywords

asparagine synthetase
8
antitumor bisn-heterocyclic
4
bisn-heterocyclic carbeneplatinumii
4
carbeneplatinumii complex
4
complex engages
4
asparagine
4
engages asparagine
4
synthetase anticancer
4
anticancer target
4
target anticancer
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!